Enjoy complimentary customisation on priority with our Enterprise License!
The global acute respiratory distress syndrome (ARDS) treatment market size is estimated to grow by USD 1.22 billion at a CAGR of 6.9% between 2023 and 2028. Our market growth and forecasting report examines historical data from 2018-2022 besides analyzing the current market scenario.
Moreover, healthcare providers are increasingly embracing lung-protective ventilation methods as standard ARDS patient care. These include using low tidal volumes, moderate to high PEEP, and driving pressure optimization to balance oxygenation and minimize ventilator-induced lung injury risks. Clinical guidelines from medical societies endorse these strategies, offering evidence-based recommendations for ventilation parameters and monitoring protocols. Advanced mechanical ventilators with tailored modes and monitoring capabilities further enhance lung-protective ventilation. These strategies, integrated into comprehensive ARDS management approaches, are expected to drive market growth.
To learn more about this report, Download Report Sample
The market faces challenges like a lack of skilled professionals and trade regulations impacting drug prices and treatment costs. ARDS affects the lungs, leading to issues like fluid accumulation and susceptibility to sepsis and pneumonia due to inhalation of harmful substances. Symptoms include low blood pressure, shortness of breath, and rapid breathing. Treatments involve mechanical ventilation, IV fluids, and inhaled medications like nitric oxide and surfactants. The World Health Organization warns of rising air pollution and exposure to harmful gases.
The market share by the hospitals pharmacies segment will be significant during the forecast period. The demand for ARDS treatment through hospital pharmacies is directly linked to the number of patients requiring hospitalization for the condition. Factors such as ARDS prevalence, respiratory illness severity, and ICU admission rates dictate the volume of treatments dispensed.
Get a glance at the market contribution of various segments Download PDF Sample
The hospitals pharmacies segment was valued at USD 1.12 billion in 2018. Hospital pharmacies are crucial due to the accessibility of medications, respiratory support devices, and therapies needed for ARDS management. Additionally, they offer investigational and off-label therapies under healthcare provider supervision, ensuring timely access to ARDS treatments and supporting multidisciplinary care teams. This pivotal role will drive growth in the hospital pharmacies segment of the acute respiratory distress syndrome treatment market.
The oral?segment will account for the largest share of this segment.?Oral medications offer a convenient and non-invasive option for ARDS management, enabling patients to self-administer treatment at home or in outpatient settings. This reduces the need for frequent hospital visits and invasive procedures, enhancing patient compliance and therapeutic outcomes. Moreover, oral medications alleviate the burden on healthcare facilities, particularly in resource-limited settings, by reducing hospital admissions and healthcare costs. Flexibility in dosing regimens allows tailored treatment plans based on individual patient needs and preferences, driving growth in the oral segment of the market.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period. North America faces a substantial burden of ARDS cases, driven by factors like aging populations, and rising incidences of pneumonia, sepsis, and trauma. The region's advanced healthcare infrastructure ensures early diagnosis and specialized treatment, improving patient outcomes. High healthcare expenditure, robust reimbursement policies, and government initiatives support access to ARDS therapies. For example, in 2023, the US government allocated USD 1.9 trillion to healthcare, while Canada announced a USD200 billion investment over ten years. Additionally, the increasing adoption of ECMO therapy enhances treatment options for severe ARDS cases.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Air Liquide SA, Boston Scientific Corporation, Dragerwerk AG and Co. KGaA, Getinge AB, Koninklijke Philips N.V., LivaNova PLC, Medtronic, Nihon Kohden Corp., SCHILLER AG, Sleepnet Corp., Stryker Corp., Vyaire Medical Inc., Smiths Group Plc, ResMed Inc., Hamilton Medical AG, GE Healthcare Technologies Inc., Fisher and Paykel Healthcare Corp. Ltd., Edesa Biotech Inc., and APEPTICO Forschung und Entwicklung GmbH
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The acute respiratory distress syndrome (ARDS) treatment market is witnessing innovations like the SonarMed airway monitoring system to address challenges such as a Lack of Skilled Professionals and stringent Trade regulations affecting Drug prices and Treatment costs. ARDS, affecting the lungs and vital organs, is caused by factors like Sepsis, Pneumonia, or inhalation of harmful substances, leading to symptoms like Low blood pressure, Shortness of breath, and Rapid breathing. Treatment involves Mechanical ventilation, IV fluids, and Inhaled medications like Nitric oxide and Surfactants. As per the World Health Organization, rising air pollution and exposure to harmful gases contribute to ARDS prevalence. Our researchers analyzed the market research and growth data with 2023 as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage.
The growing interest in immunomodulatory therapies is the primary trend shaping the market. Immunomodulatory therapies are vital treatments that regulate the immune system's response in various medical conditions, including autoimmune diseases, infections, cancer, and organ transplantation. These therapies, aiming to either enhance or suppress immune activity, are integral components of multimodal treatment approaches for ARDS. Combining immunomodulation with standard ARDS treatments optimizes outcomes by addressing the complex nature of ARDS pathophysiology. Ongoing research focuses on identifying novel immunomodulatory agents and targets, including anti-inflammatory drugs, cytokine inhibitors, and biologic agents.
Furthermore, clinical trials evaluate the safety and efficacy of these therapies alone or in combination with standard treatments to improve patient outcomes. Advances in immunology uncover new therapeutic targets, such as pro-inflammatory cytokines and immune cell receptors, offering promising avenues for mitigating ARDS-associated inflammation and lung injury. The growing interest in immunomodulatory therapies underscores their potential to drive growth in the market.
The heterogeneity of the patient population is the major challenge that affects market expansion. Managing ARDS patients presents challenges due to their heterogeneity in underlying causes, disease severity, and treatment responses. Developing effective therapies requires personalized or stratified treatment strategies, considering variations in age, sex, comorbidities, and disease etiology. Clinical trials must carefully account for patient heterogeneity to interpret results accurately. Comorbidities and pre-existing conditions further complicate treatment outcomes.
Additionally, patients may respond differently to standard therapies. Limited biomarkers hinder stratification and treatment decisions. Addressing ARDS heterogeneity demands personalized diagnostics, tailored treatment plans, and multidisciplinary care, posing challenges for healthcare systems. These factors will hinder the growth of the market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
The global respiratory distress syndrome treatment market is witnessing significant growth, driven by rising disease prevalence and revenue growth. Technological advancements in ventilator strategies and endotracheal tube occlusion are enhancing patient care. Research and drug development, alongside government awareness campaigns, are pivotal in addressing challenges like fluid accumulation in alveoli. With home healthcare and specialty clinics playing crucial roles, critical care units are witnessing increased admissions. Acoustic technology and approved drugs further propel market trends.
Additionally, the global acute respiratory distress syndrome market is influenced by various factors, including healthcare investment and growth drivers. However, challenges such as lack of awareness hinder progress. Effective market segmentation aids in targeting specific end users, including private market key players and critical care unit admissions. Addressing issues like extreme tiredness requires innovative treatments and heightened awareness campaigns to improve patient outcomes and enhance the overall management of acute respiratory distress syndrome.
Acute Respiratory Distress Syndrome Treatment Market Scope |
|
Report Coverage |
Details |
Page number |
161 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.9% |
Market growth 2024-2028 |
USD 1.22 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
6.2 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key countries |
US, Germany, UK, France, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Air Liquide SA, Athersys Inc., Boston Scientific Corporation, Dragerwerk AG and Co. KGaA, Getinge AB, Koninklijke Philips N.V., LivaNova PLC, Medtronic, Nihon Kohden Corp., SCHILLER AG, Sleepnet Corp., Stryker Corp., Vyaire Medical Inc., Smiths Group Plc, ResMed Inc., Hamilton Medical AG, GE Healthcare Technologies Inc., Fisher and Paykel Healthcare Corp. Ltd., Edesa Biotech Inc., and APEPTICO Forschung und Entwicklung GmbH |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.